Health and Economic Outcomes of Pembrolizumab in the Treatment of Metastatic Non-small Cell Lung Cancer (mNSCLC) and Melanoma in Italy.
Martina PaolettiChiara BiniAndrea MarcellusiFrancesco Saverio MenniniPublished in: Clinical drug investigation (2024)
The analysis demonstrated that, compared with chemotherapy, pembrolizumab is more cost effective in Italy as a first-line treatment in patients with metastatic squamous or non-squamous NSCLC and, if compared with watchful waiting, as adjuvant treatment in patients with stage III melanoma. The present analysis suggested that pembrolizumab use could lead to important health benefits for patients while offsetting a portion of cancer care costs.
Keyphrases
- advanced non small cell lung cancer
- healthcare
- small cell lung cancer
- public health
- mental health
- end stage renal disease
- high grade
- squamous cell carcinoma
- early stage
- newly diagnosed
- low grade
- combination therapy
- peritoneal dialysis
- metabolic syndrome
- patient reported outcomes
- rectal cancer
- tyrosine kinase
- patient reported
- basal cell carcinoma